Business
Alto Neuroscience Reports Full Year 2025 Financial Results and Recent Business Highlights
MOUNTAIN VIEW, Calif., March 16, 2026--Alto Neuroscience, Inc. ("Alto") (NYSE: ANRO), a clinical-stage biopharmaceutical company focused on the development of novel precision medicines for neuropsychiatric disorders, today reported financial results for the full year ended December 31, 2025, and highlighted recent progress across its pipeline of clinical-stage product candidates.
About this update from Alto Neuroscience, Inc.
[{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":1659,"height":537,"url":"https://media.zenfs.com/en/business-wire.com/ce7837c20cbb0e7d43a30409ea02da5c"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/YkPVI8MkndBQkPA0rCV4jw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTMxMTtjZj13ZWJw/https://media.zenfs.com/en/business-wire.com/ce7837c20cbb0e7d43a30409ea02da5c","width":960,"height":311},"lightbox":{"url":"https://s.yimg.com/ny/api/res/1.2/gKJo1HemqeZGZpH8KCV6eA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTI0MDA7aD03NzY7Y2Y9d2VicA--/https://media.zenfs.com/en/business-wire.com/ce7837c20cbb0e7d43a30409ea02da5c","width":1200,"height":388}},"lazy":false},{"type":"text","content":"– Acquisition of ALTO-207 targets Treatment-Resistant Depression (TRD) with a clinically-validated mechanism; Phase 2b trial on track to be initiated in the first half of 2026 –","length":177,"tagName":"p","attribs":{}},{"type":"text","content":"– External PAX-D study published in The Lancet Psychiatry demonstrated a 0.87 effect size for the core mechanism of ALTO-207; this effect represents a significantly larger effect size than current standard-of-care treatments –","length":226,"tagName":"p","attribs":{}},{"type":"text","content":"– ALTO-101 granted FDA Fast Track Designation for CIAS; Topline Phase 2 Proof-of Concept data expected around the end of 1Q 2026 –","length":130,"tagName":"p","attribs":{}},{"type":"text","content":"– Year-end cash balance of $177 million expected to fund planned operations into 2028, covering four key data readouts across Alto’s precision psychiatry pipeline –","length":164,"tagName":"p","attribs":{}},{"type":"text","content":"MOUNTAIN VIEW, Calif., March 16, 2026--(BUSINESS WIRE)--Alto Neuroscience, Inc. ("Alto") (NYSE: ANRO), a clinical-stage biopharmaceutical company focused on the development of novel precision medicines for neuropsychiatric disorders, today reported financial results for the full year ended December 31, 2025, and highlighted recent progress across its pipeline of clinical-stage product candidates.","length":409,"tagName":"p"},{"type":"text","content":""Alto enters 2026 with a very strong clinical and financial foundation," said Amit Etkin, M.D., Ph.D., founder and chief executive officer of Alto Neuroscience. "The acquisi...